Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use
Authors
Keywords
Cardiovascular disease, Cross sectional analysis, Empagliflozin, EMPA-REG OUTCOME, Type 2 diabetes, SGLT2
Journal
Diabetes Therapy
Volume 8, Issue 2, Pages 365-376
Publisher
Springer Nature
Online
2017-03-21
DOI
10.1007/s13300-017-0254-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
- (2017) Andrew McGovern et al. Diabetes Therapy
- Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Comparing Trial and Real World Use (Study Protocol)
- (2017) Andrew McGovern et al. Diabetes Therapy
- Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
- (2016) A.J. Scheen DIABETES & METABOLISM
- Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
- (2016) Sunder Mudaliar et al. DIABETES CARE
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials
- (2016) Kristina Johnsson et al. POSTGRADUATE MEDICINE
- Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
- (2016) Andrew McGovern et al. BMJ Open
- Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel network: a cohort profile
- (2016) Ana Correa et al. BMJ Open
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Basing approval of drugs for type 2 diabetes on real world outcomes
- (2015) Andrew McGovern et al. BMJ-British Medical Journal
- Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries
- (2015) Ugne Sabale et al. Primary Care Diabetes
- Basing approval of drugs for type 2 diabetes on real world outcomes
- (2015) Andrew McGovern et al. BMJ-British Medical Journal
- Integrating electronic health record information to support integrated care: Practical application of ontologies to improve the accuracy of diabetes disease registers
- (2014) Siaw-Teng Liaw et al. JOURNAL OF BIOMEDICAL INFORMATICS
- Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action
- (2014) Yoshihito Fujita et al. Journal of Diabetes Investigation
- Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes
- (2013) Despoina Vasilakou et al. ANNALS OF INTERNAL MEDICINE
- Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands
- (2013) Heleen G. M. van Haalen et al. CLINICAL DRUG INVESTIGATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation